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p://dx.doi.org/10.1016/j.cmi.2015.06.008IntroductionCandidaemia still contributes to morbidity, mortality, and
increased costs, despite the introduction of potent antifungal
drugs in recent decades [1–4]. Candida species causing noso-
comial bloodstream infections ranked fourth in the USA in
2002 and seventh in a study from Europe in 2000 [5,6]. In the
Nordic and other European countries, the incidence of candi-
daemia varies between 1.7 and 4.9 per 100 000 inhabitantsious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Hesstvedt et al. Candidaemia in Norway 939[7–13]. An exception is Denmark, with an incidence of 10/
100 000 inhabitants in 2011 [14].
Candida albicans is the most commonly identiﬁed species
causing candidaemia globally, but with a decreasing frequency
[1–6,15–17]. However, the epidemiology of candidaemia varies
with geographical region. Candidaemia due to Candida glabrata
is common in the northern hemisphere, whereas the incidence
of candidaemia due to Candida parapsilosis is increasing in Latin
America and southern parts of the world [15,16]. Age, un-
derlying malignancy and prior antifungal therapy inﬂuence the
species distribution, regardless of geographical location. This
partly explains differences in epidemiology in studies from small
centres vs. larger regions or countries [6,9,18,19].
In Norway, with a modest population of 5 051 275 million
inhabitants by 2012, there has been an established national
laboratory network monitoring candidaemia since 1991. Its
longitudinal quality provides important knowledge that is
essential for proper antifungal stewardship. The aim of this
study was to investigate the incidence, species distribution and
susceptibility to antifungal drugs in Norwegian Candida isolates
from 2004 to 2012, and to compare these data with those
previously published from 1991 to 2003, covering a 22-year
period.Materials and methodsSurveillance and collection of isolates
A national network, the Norwegian Yeast Study Group, has
existed since 1991, comprising all 22 departments of medical
microbiology in Norway, six of which are situated at university
hospitals. Candida isolates retrieved from blood cultures at any
Norwegian hospital were sent to the Norwegian Mycological
Reference Laboratory at Oslo University Hospital, Rik-
shospitalet, for species conﬁrmation and susceptibility testing.
The isolates were stored at −70°C. Two automated blood
culture systems were used in the 22 different laboratories from
2004 until 2012. Thirteen laboratories used Bactec (Becton
Dickinson Microbiology Systems, Sparks, MD, USA), and nine
used the BacT/Alert system (bioMerieux, Marcy l’Etoile,
France). None of the laboratories changed their blood culture
systems during the current study period.Patients and episodes
For each Candida isolate, information on the patient’s gender
and age was retrieved. An episode of candidaemia was deﬁned
as at least one blood culture positive for Candida species, and
episodes were considered to be distinct if they occurred at
least 30 days apart.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologySpecies identiﬁcation
Species identiﬁcation was based on culture on Sabouraud
glucose agar, culture on Chrome Agars (BBL CHROMagar
Candida; BD Diagnostics, Franklin Lakes, NJ, USA), germ tube
production, microscopic morphology on corn meal Tween,
appearance on PAL medium, VITEK 2, and API 32 C (bio-
Merieux). From 2011, matrix-assisted laser desorption ioniza-
tion time-of-ﬂight mass spectrometry (Bruker Daltonics,
Fremont, CA, USA) replaced VITEK 2 and API 32 C for the
identiﬁcation of the isolates. In isolates not identiﬁed as noted
above, 18S rDNA PCR and sequencing were performed for
species identiﬁcation.
Susceptibility testing
From 2004 onwards, the Etest method (bioMerieux) was used
for all antifungals (amphotericin B, ﬂuconazole, voriconazole,
caspofungin, micafungin, and anidulafungin). Susceptibility
testing was started in 2005 for caspofungin, in 2009 for ani-
dulafungin, and in 2009 for micafungin. Supplementary suscep-
tibility testing of frozen isolates from 2004–2009 for
anidulafungin, as a marker for the echinocandin class, was
performed in 2013. Results from susceptibility testing from
2004–2012 were categorized according to updated clinical
breakpoints from the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) (2014. Antifungal Agents.
Breakpoint tables for interpretation of MICs. Version 7.0.
http://eucast.org).
National consumption of antifungal drugs
Data on consumption of antifungal drugs were obtained from
the Norwegian Institute of Public Health (http://www.
legemiddelforbruk.no).
Statistics
Population estimates on 1 January each year from Statistics
Norway (http://www.ssb.no) were used to calculate the inci-
dence of candidaemia. The chi-square test was used to compare
changes in incidence rate and species distribution between
periods. STATA version 11.0 (Stata, College Station, TX, USA)
was used for statistical analyses. A p-value of <0.05 was
considered to be statistically signiﬁcant.ResultsEpidemiology
From 2004 to 2012, 1724 Candida isolates from 1677 episodes
of candidaemia were obtained from 1653 patients (58% males;
median age, 67 years; range, 0–102 years). In 2004, the inci-
dence was 3.2/100 000 inhabitants; this increased to 3.6/and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 938–945
FIG. 1. Comparison of age-speciﬁc incidence per 100 000 inhabitants
per year between two periods (1991–2003 and 2004–2012). *p 0.001;
**p 0.01; ***p <0.001.
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4.2/100 000 inhabitants (Table 1). The average incidence was
3.9/100 000 inhabitants or 0.22/1000 admissions (range,
0.18–0.25). There was a gradual increase in incidence with age,
with rates being highest at the extremes of ages (Fig. 1). The
majority of all isolates (64 %) were detected in the >59-year age
groups.
Twenty-two patients (1.3%) had two or more episodes of
candidaemia occurring at least 1 month apart. In total, 20 pa-
tients had two episodes of candidaemia, and two patients had
three episodes of candidaemia. Nine of these episodes occurred
within 1–3 months of the ﬁrst episode, nine episodes occurred
between 3 and 6 months, and six episodes occurred after 6
months.
Species distribution
The four most common species found were C. albicans,
C. glabrata, C. parapsilosis, and Candida tropicalis, accounting for
93.3% of all isolates. C. albicans was the most common species
found in all age groups, accounting for 67.7% (Table 2).
C. parapsilosis was the second most common species found in
patients aged <1 year, whereas C. glabrata was the second most
common species found in all >29-year age groups (Table 3).
The proportion of candidaemias due to C. glabrata increased
with age, accounting for 17% in the >59-year age group. No
signiﬁcant increase in incidence was seen in the <1-year age
group.
For 97% of the candidaemias, only one Candida species was
isolated. In 47 episodes (3%), two different species were iso-
lated. C. albicans was isolated together with C. glabrata in 26
episodes, together with C. parapsilosis in seven episodes,
together with C. tropicalis in seven episodes, and together with
C. dubliniensis in three episodes. In only four episodes was
C. albicans not one of the two species isolated.
Two previous studies on candidaemia have reported varia-
tions in the isolation rate of C. glabrata with blood cultureTABLE 1. Annual incidence of candidaemia by age group in Norwa
Age group (years)
No. of episodes per 100 000 population (no. of cases)
2004 2005 2006 2007 200
<1 5.3 (3) 8.9 (5) 6.8 (5) 8.5 (5) 9.9
1–9 0.3 (2) 0.2 (1) 0.4 (1) 0.9 (5) 0
10–19 0.5 (3) 1.0 (6) 0.5 (3) 1.0 (6) 1.0
20–29 1.2 (7) 1.3 (7) 1.4 (8) 1.4 (8) 1.3
30–39 1.0 (7) 2.2 (15) 1.3 (9) 0.4 (3) 1.2
40–49 2.3 (15) 3.2 (21) 2.3 (15) 2.5 (17) 1.7
50–59 3.3 (20) 4.0 (24) 3.7 (22) 4.1 (25) 4.6
60–69 6.8 (27) 10.8 (45) 8.8 (39) 9.0 (42) 9.1
70–79 14.1 (41) 11.8 (34) 19.5 (56) 18.9 (54) 18.2
80–89 9.3 (17) 12.9 (24) 16.6 (31) 20.0 (37) 18.5
>90 13.5 (4) 42.2 (13) 22.0 (7) 9.0 (3) 11.5
All groups 3.2 (146) 4.2 (195) 4.2 (196) 4.3 (205) 4.2
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectsystems [20,21]. C. glabrata accounted for 11% of the isolates in
laboratories using the Bactec blood culture system, and for 19%
of isolates in laboratories using the BacT/Alert blood culture
system.
Antifungal susceptibility
The results of the MIC distribution and antifungal susceptibility
testing from 2004 to 2012 are shown in Table 4. According to
EUCAST breakpoints (Table 5), the vast majority of isolates
(1613) were susceptible to amphotericin B, deﬁned by an of
MIC  1 mg/L, the exceptions being eight Candida krusei iso-
lates, ﬁve C. parapsilosis isolates, ﬁve C. tropicalis isolates, and
one C. glabrata isolate. All but three C. albicans isolates (98.8%)
were susceptible to ﬂuconazole. The majority of isolates
resistant to ﬂuconazole were C. glabrata (61%, MIC > 32 mg/L)
and C. krusei (26%, MIC > 2 mg/L). As many as 89.2% of
C. parapsilosis isolates were found to be intermediately sus-
ceptible to anidulafungin (2 < MIC  4 mg/L). Few C. glabrata
isolates (2.4%) were resistant to anidulafungin, and, overall, only
1.8% of all isolates showed resistance to anidulafungin, as
marker for the echinocandin class.y from 2004 to 2012
8 2009 2010 2011 2012 Total
(6) 6.4 (4) 6.0 (4) 8.3 (5) 5.0 (3) 7.5 (40)
0.4 (2) 0.6 (3) 0.2 (1) 0.2 (1) 0.3 (16)
(6) 0.3 (2) 0.5 (3) 0.5 (3) 0.5 (3) 0.6 (34)
(8) 0.7 (4) 1.1 (7) 1.4 (9) 1.5 (10) 1.25 (68)
(8) 1.0 (7) 0.6 (4) 2.1 (14) 1.8 (12) 1.3 (79)
(12) 3.3 (23) 2.3 (16) 2.6 (19) 2.3 (17) 2.5 (155)
(28) 4.1 (25) 3.2 (20) 3.5 (22) 4.0 (25) 3.8 (211)
(44) 8.0 (40) 7.2 (38) 7.7 (41) 6.6 (36) 8.2 (352)
(53) 16.2 (53) 16.0 (47) 16.1 (48) 9.5 (29) 15.7 (412)
(34) 16.3 (30) 13.7 (25) 13.2 (24) 21.7 (39) 15.8 (261)
(4) 11.2 (4) 13.1 (5) 7.5 (3) 14.6 (6) 15.5 (49)
(200) 4.0 (194) 3.6 (172) 3.9 (189) 3.6 (180) 3.9 (1677)
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 938–945
TABLE 2. Distribution of Candida species from blood cultures in Norway in 2004–2012 vs. 1991–2003
Species 2004 2005 2006 2007 2008 2009 2010 2011 2012 Total 2004–2012 (%) Total 1991–2003 (%)
C. albicans 102 123 130 156 144 140 113 137 123 1168 (67.7) 987 (69.8)
C. glabrata 18 39 35 23 28 32 34 23 23 255 (14.8) 187 (13.2)
C. tropicalis 13 12 16 11 13 13 12 12 10 112 (6.5) 95 (6.7)
C. parapsilosis 6 3 9 9 11 10 7 13 6 74 (4.3) 82 (5.8)
C. dubliniensis 6 7 4 4 5 4 1 7 8 46 (2.7) 8 (0.6)
C. lusitaniae 4 4 3 3 1 0 2 3 5 25 (1.5) 2 (0.2)
C. krusei 1 2 5 1 4 3 5 0 2 23 (1.3) 22 (1.5)
C. guilliermondii 0 3 0 0 0 2 2 0 1 8 (0.5) 8 (0.6)
C. kefyr 1 3 0 0 2 0 0 0 1 7 (0.4) 7 (0.5)
Other Candida species 1 0 0 1 0 1 0 1 2 6 (0.3)a 17 (1.2)b
Total 152 196 202 208 208 205 176 196 181 1724 1415
aFor 2004–2012, other Candida species were as follows: C. pelliculosa (2), C. famata (1), C. lipolytica (1), C. magnolia (1), and C. norvegensis (1).
bFor 1991–2003, other Candida species were as follows: C. norvegensis (8), C. blankii (1), C. inconspicua (1), C. sake (2), C. sphaerica (1), and four unidentiﬁed isolates.
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use
The total consumption of antifungal drugs for systemic use
(ATC group J02A) increased by 78%, from 53.0 deﬁned daily
doses (DDD) per 1000 inhabitants in 2004, to 94.2 DDD in
2012. From 2004 to 2012, the consumption of ﬂuconazole
doubled from 35.2 to 70.2 DDD. With exclusion of ketoco-
nazole, ﬂuconazole consumption alone accounted for 88% of
the total use of antifungal drugs for systemic use in Norway in
2012. From 2007 to 2012, the consumption of amphotericin B
and the consumption of echinocandins increased three-fold,
from 1.0 to 3.3 DDD and from 0.7 to 1.97 DDD, respec-
tively. By 2012, the echinocandins were used as follows: cas-
pofungin, 1.14 DDD; micafungin, 0.77 DDD; and anidulafungin,
0.06 DDD.DiscussionWhereas others have reported an increase in the incidence of
candidaemia correlating with non-albicans candidaemia, we
demonstrate in this study a signiﬁcant, but modest, increase in
the average incidence of candidaemia, from 2.4/100 000 in-
habitants in the period 1991–2003 to 3.9/100 000 inhabitants inTABLE 3. Species distribution of the Candida species by age group
Species
Age group (years)
<1 1–9 10–19 20–29 30–39
C. albicans 32 (80) 9 (56.1) 23 (66) 44 (64) 57 (68)
C. glabrata 1 (2.5) — 2 (6) 4 (6) 13 (16)
C. tropicalis 1 (2.5) 1 (6.3) 2 (6) 4 (6) 5 (6)
C. parapsilosis 4 (10) 5 (31.3) 4 (11) 7 (10) 1 (1)
C. lusitaniae 1 (2.5) — 1 (2.5) 2 (3) —
C. dubliniensis — 1 (6.3) 2 (6) 3 (4) 7 (8)
C. krusei 1 (2.5) — — 2 (3) —
Other Candida speciesa — — 1 (2.5) 3 (4) 1 (1)
Total no. of isolates 40 16 35 69 84
aOther Candida species were as follows: C. guillermondi (8), C. kefyr (7), C. pelliculosa (2), C. f
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologythe period 2004–2012 [3,9,10,14]. The species distribution
remained stable, without any emerging antifungal drug
resistance.
A population-based study in 2008–2013 from the USA re-
ported a much higher incidence than reported in Norway. In a
recent study from Atlanta and Baltimore, where the incidence
rates were especially high, declines in the average annual inci-
dence from 14.1/100 000 inhabitants to 9.5/100 000 inhabitants
and from 30.9/100 000 inhabitants to 14.4/100 000 inhabitants,
respectively, were reported [22]. Improvements in healthcare
delivery (catheter insertion and maintenance) were the main
explanation for the large reductions. European studies from
2002 to 2005 reported a more modest incidence. A Spanish
study reported a regional incidence of 4.3/100 000 inhabitants,
and a national Scottish study reported an incidence of 4.8/
100 000 inhabitants [7,23]. The Nordic countries have reported
a low, but increasing, incidence. National studies in Finland in
the period 1995–2007 reported an increase in the incidence
from 1.7/100 000 inhabitants to 2.9/100 000 inhabitants. In
Iceland, in the period 1980–1999, the national incidence
increased from 1.4/100 000 inhabitants to 4.9/100 000 in-
habitants, and in Sweden the national incidence in 2005 was 4.2/
100 000 inhabitants [8,11–13]. In 2012, Denmark reported a
consistently high incidence, of 10/100 000 inhabitants [14]. The(no. (%))
40–49 50–59 60-69 70–79 80–89 >90
102 (63) 163 (76) 256 (71) 281 (66) 176 (65) 25 (51)
22 (13) 24 (11) 42 (12) 72 (17) 61 (23) 14 (29)
10 (6) 11 (5) 22 (6) 40 (9) 13 (5) 3 (6)
6 (4) 5 (2) 15 (4) 16 (4) 8 (3) 3 (6)
5 (3) 1 (1) 5 (1) 5 (1) 4 (1.5) 1 (2)
10 (6) 5 (2) 7 (2) 6 (1) 4 (1.5) 2 (4)
1 (1) 3 (2) 10 (3) 1 (1) 2 (0.5) 1 (2)
7 (4) 2 (1) 3 (1) 3 (1) 1 (0.5) —
163 214 361 424 269 49
amata (1), C. liposa (1), C. magnolia (1), and C. norvegensis (1).
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 938–945
TABLE 4. MIC distribution and susceptibility of the candidaemia isolates to four different antifungal drugs from 2004 to 2012a
No.
MIC (mg/L)
£0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1 2 4 8 16 ‡32 S (%) I (%) R (%)
Amphotericin B
C. albicans 1168 1 5 16 109 449 551 37 b b b b b 1168 (100) 0 0
C. dubliniensis 46 1 3 4 8 14 16 — — —
C. tropicalis 112 4 17 46 40 5b b b b b 107 (95.5) 0 5 (4.5)
C. parapsilosis 74 1 11 31 26 5b b b b b 69 (93.2) 0 5 (6.8)
C. lusitaniae 25 1 1 5 9 8 1 — — —
C. glabrata 255 1 1 3 12 62 164 11 1b b b b b 254 (99.6) 0 1 (0.4)
C. krusei 23 1 1 13 7b 1b b b b 15 (65.2) 0 8 (34.8)
C. guilliermondii 8 1 2 4 1 — — —
Candida speciesc 13 1 2 5 2 2 1 — — —
Total 1724 1 1 2 11 28 144 568 819 129 18 2 0 0 1 1613 (98.8) 0 19 (1.2)
Fluconazole
C. albicans 1168 1 1 14 214 600 312 20 3 d 1b 1b 1b 1165 (99.7) 0 3 (0.3)
C. dubliniensis 46 1 4 13 23 3 2 d b b b 46 (100) 0 0
C. tropicalis 112 3 17 61 21 6 d b b 2b 108 (96.4) 2 (1.8) 2 (1.8)
C. parapsilosis 74 6 26 21 14 4 1d b 1b 1b 71 (96) 1 (1.3) 2 (2.7)
C. lusitaniae 25 2 8 9 4 1 1d b b b 24 (96) 1 (1) 0
C. glabrata 255 d d d d d d 1d 1d 5d 25d 72d 66d 22d 63d 0 201 (78.8) 54 (21.2)
C. krusei 23 d b 5b 18b 0 0 23 (100)
C. guilliermondii 8 1 2 1 1d b 1b 2b 4 (50) 1 (7.7) 3 (37.5)
Candida speciesc 13 3 4 1 3d b 1b 1b 8 (61.5) 3 (23.1) 2 (15.4)
Total 1724 1 1 1 18 238 678 412 68 41 80 67 31 88 1426 (82.7) 209 (12.1) 89 (5.2)
Voriconazole
C. albicans 1168 15 122 688 308 21 6 5 1b 2b b b b b b b 1165 (99.8) 0 3 (0.2)
C. dubliniensis 46 2 28 12 2 1 1 — — —
C. tropicalis 112 1 2 11 25 50 16 5b 1b b 1b b b b b 105 (93.8) 0 7 (6.2)
C. parapsilosis 74 3 21 24 14 8 1 2b 1b b b b b b b 71 (95.9) 0 3 (4.1)
C. lusitaniae 25 3 9 5 3 2 1 2 — — —
C. glabrata 255 2 4 22 58 78 36 8 6 10 4 6 21 — — —
C. krusei 23 1 11 8 2 1 — — —
C. guilliermondii 8 2 1 1 1 1 2 — — —
Candida speciesc 13 5 3 1 1 1 1 1 — — —
Total 1724 15 131 753 365 72 91 82 101 50 10 10 11 4 6 23 1341 (99.0) 13 (1.0)
Anidulafungin
C. albicans 1168 383 557 181 31 4 4b 3b 3b b 2b b b b b b 1156 (98.9) 0 12 (1.2)
C. dubliniensis 46 1 9 29 6 1 — — —
C. tropicalis 112 19 83 8 b b 1b b 1b b b b b 110 (98.2) 0 2 (1.8)
C. parapsilosis 74 d d 1d d d d 1d 11d 21d 19d 13d 1b 4b 3b 0 66 (89.2) 8 (10.8)
C. lusitaniae 25 9 6 5 5 — — —
C. glabrata 255 8 3 41 183 13 1 1b 1b 2b b b 1b 1b b b 249 (97.6) 0 6 (2.4)
C. krusei 23 18 5 b b b b b b b b b 23 (100) 0 0
C. guilliermondii 8 2 2 2 1 1 — — —
Candida speciesb 13 1 1 1 5 3 1 1 — — —
Total 1724 393 570 270 305 52 21 13 10 17 24 22 16 3 4 4 1538 (94.2) 66 (4) 28 (1.8)
I, intermediately resistant; R, resistant; S, susceptible.
aEUCAST breakpoints from 2014 were used.
bThe distribution of resistant isolates.
cOther Candida species were as follow: C. kefyr (7), C. pelliculosa (2), C. lipolytica (1), C. famata (1), C. magnolia (1) and C. norvegensis (1).
dThe distribution of intermediately susceptible isolates.
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or other European countries may be explained by differences in
healthcare systems, demographics, and risk factors, such as
frequency of intensive-care unit admission, intravenous lines,
abdominal surgery, malignancies, organ transplants, and anti-
microbial use [23–25]. However, many of these factors are
considered to be similar in the Nordic countries. Further
studies are needed to determine the reasons for these differ-
ences, but a contributor to the low candidaemia rate in Norway
may be our restrictive use of antimicrobial drugs. Our study
also reports long-term national data, which excludes the bias
that may occur in short-term studies and in studies from
geographically smaller regions or selected patient populations.
A marked increase was seen in patients aged >60 years.
Despite a 1% decrease in the Norwegian population aged >67
years from 1991 to 2012, the incidence among the elderly hasClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectincreased. Malignancies and surgical procedures are common
predisposing factors for candidaemia, and are, overall, more
frequent in the elderly. Additionally, more extensive use of
broad-spectrum antimicrobials, aggressive chemotherapy and
administration of intravenous lines may have contributed to
increasing the risk of candidaemia in the elderly.
The species distribution of the isolates overall remained
stable from 1991 to 2012, as C. albicans, C. glabrata,
C. parapsilosis and C. tropicalis accounted for 93.3–95.5% of all
isolates [9,10]. Despite the global trend of decreasing frequency
of C. albicans candidaemias, we found high proportions of
C. albicans in all age groups, and similar C. glabrata proportions.
More similar to the global trends, a shift in species distribution
was seen in Denmark in 2012, with a decreasing proportion of
C. albicans (52.1%) and increasing proportion of C. glabrata
(28%) [14]. The explanation for the difference in speciesious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 938–945
TABLE 5. Clinical breakpoints for common Candida species
from CLSI [30] and EUCAST
CLSI EUCAST
Clinical breakpoints (mg/L)
Clinical
breakpoints
(mg/L)
Candida species S  SDD I R  S  R >
C. albicans
Amphotericin B ND — — ND 1 1
Anidulafungin 0.25 — 0.5 1 0.03 0.03
Fluconazole 2 4 — 8 2 4
Voriconazole 0.12 — 0.25–0.5 1 0.12 0.12
C. glabrata
Amphotericin B ND — — ND 1 1
Anidulafungin 0.12 — 0.25 0.5 0.06 0.06
Fluconazole — 32 — 64 0.002 32
Voriconazole ND — — ND IE IE
C. parapsilosis
Amphotericin B ND — — ND 1 1
Anidulafungin 2 — 4 8 0.002 4
Fluconazole 2 4 — 8 2 4
Voriconazole 0.12 — 0.25–0.5 1 0.12 0.12
C. tropicalis
Amphotericin B ND — — ND 1 1
Anidulafungin 0.25 — 0.5 1 0.06 0.06
Fluconazole 2 4 — 8 2 4
Voriconazole 0.12 — 0.25–0.5 1 0.12 0.12
C. krusei
Amphotericin B ND — — ND 1 1
Anidulafungin 0.25 — 0.5 1 0.06 0.06
Fluconazolea NR NR NR NR NR NR
Voriconazole 0.5 — 1 2 IE IE
C. guilliermondii
Amphotericin B ND — — ND IE IE
Anidulafungin 2 — 4 8 IE IE
Fluconazole NR — — NR IE IE
Voriconazole NR — — NR IE IE
Non-species-related breakpoints
Fluconazole — — — — 2 4
EUCAST, European Committee on Antimicrobial Susceptibility Testing;
I, intermediately resistant; IE, insufﬁcient evidence that this speciﬁc species is a good
target for therapy with the drug; ND, no deﬁned breakpoints from the CLSI;
NR, susceptibility testing is not recommended, as the species is a poor target for
therapy with this speciﬁc drug; R, resistant; S, susceptible; SDD, susceptible-dose-
dependent.
aC. krusei is considered to be intrinsically resistant to this compound.
CMI Hesstvedt et al. Candidaemia in Norway 943distribution between Norway and Denmark is not obvious, as
the countries have similar demographics and healthcare sys-
tems. However, extended use of ﬂuconazole may lead to se-
lection pressure and increased proportions of C. glabrata
[14,23]. By 2012, ﬂuconazole consumption alone accounted for
70.2 DDD in Norway and 186 DDD in Denmark (http://www.
medstat.dk), possibly explaining some of the differences.
When comparing the two time periods, we found a signiﬁ-
cant increase in the number of C. glabrata isolates, from 7% to
16%, only in the 30–40-year age group [9]. Whether this re-
ﬂects selective pressure resulting from increased ﬂuconazole
use is unknown. Although we did not ﬁnd a signiﬁcant increase
in the number of C. glabrata candidaemia cases in the oldest age
groups, it still occurs in one of ﬁve of patients aged >70 years.
The rates of isolation of C. glabrata species were still higher
in laboratories using BacT/Alert (18.1% in 1991–2003) than in
those using the Bactec blood culture system (9% in
1991–2003). This may imply that Bactec fungal medium is not
routinely used to improve C. glabrata detection, despite Nor-
wegian recommendations.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyMethods for susceptibility testing and categorizing suscepti-
bility results changed from 1991 to 2012, making comparison
between time periods difﬁcult. However, acquired resistance to
ﬂuconazole among C. albicans isolates is still rare. The ﬂucon-
azole MIC distributions for C. albicans and C. glabrata remained
stable during the 22-year period (1991–2003: C. albicans,
MIC50 < 0.5 mg/L, MIC90 < 1 mg/L, range 0.25–4 mg/L;
C. glabrata, MIC50 < 16 mg/L, MIC90 < 64 mg/L, range 1–64 mg/
L), despite the increase in ﬂuconazole use from 2004 to 2012.
However, according to updated EUCAST breakpoints, none of
the C. glabrata isolates from 2004–2012 were susceptible to
ﬂuconazole, and 80% were intermediately susceptible, a fact
that is very relevant for decisions on whether to use empirical
treatment, particularly for the elderly.
Overall, resistance to anidulafungin among our isolates was
rare, in accordance with recent European studies, and as ex-
pected, given that the consumption of echinocandins in Norway
is low [14,26]. However, resistance to echinocandins in
C. glabrata isolates is emerging in the USA, and needs careful
monitoring in our setting as well [27].
We found that 80% of our C. parapsilosis isolates were
intermediately susceptible to anidulafungin. The species is less
virulent than other Candida species, and no signiﬁcant difference
was found in the outcome of C. parapsilosis candidaemia in a
treatment evaluation study on anidulafungin vs. ﬂuconazole.
Thus, the clinical implication of this ﬁnding is uncertain [28].
Surprisingly, 34% of the C. krusei isolates were resistant to
amphotericin B, when they were expected to be susceptible.
The isolates were distributed without any outliers, with seven
isolates being only one dilution step and one isolate being two
dilution steps above the EUCAST breakpoint (1 mg/L). The
Etest method seems to bisect C. krusei isolates, and our ﬁnding
is most probably due to the susceptibility testing method,
rather than representing a separate resistant population [25].
When EUCAST breakpoints are used for susceptibility cate-
gorization, the species distribution needs to mirror the EUCAST
distributions, to avoid misclassiﬁcation of susceptibility. For
certain drug–microrganism combinations (C. tropicalis vs. vor-
iconazole and anidulafungin), the Norwegian isolates were
distributed around lowerMICs than the EUCAST isolates (http://
www.eucast.org/mic_distributions/). Hypothetically, a few iso-
lates with low-grade resistance can bemisclassiﬁed as susceptible
because of this [25,29]. However, with awareness of the technical
variation,we ﬁnd the Etestmethod to be sufﬁcient and reliable for
susceptibility testing in our epidemiological setting.
In conclusion, the overall incidence of candidaemias in
Norway remains modest. The increase is mainly observed in
patients aged >60 years. The species distribution is stable and
dominated by C. albicans. In spite of this, the use of ﬂuconazole
in Norway is increasing, but without acquired resistance being aand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 938–945
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proper antifungal stewardship. However, a study on morbidity
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